NCT07187778View on ClinicalTrials.gov

Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 28, 2026

Primary Completion Date

July 19, 2027

Study Completion Date

July 19, 2029

Conditions
Clear Cell Renal Cell Carcinoma
Interventions
DRUG

Pembrolizumab

Oral administration

DRUG

Belzutifan

Oral administration

Trial Locations (1)

77030

The University of Texas M. D. Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER